Zobrazeno 1 - 10
of 184
pro vyhledávání: '"Rama, Suresh"'
Autor:
Xiuli Zhang, S. Peter Goedegebuure, Michael Y. Chen, Rashmi Mishra, Felicia Zhang, Yik Yeung Yu, Kartik Singhal, Lijin Li, Feng Gao, Nancy B. Myers, Tammi Vickery, Jasreet Hundal, Michael D. McLellan, Mark A. Sturmoski, Samuel W. Kim, Ina Chen, Jesse T. Davidson, Narendra V. Sankpal, Stephanie Myles, Rama Suresh, Cynthia X. Ma, Ademuyiwa Foluso, Andrea Wang-Gillam, Sherri Davies, Ian S. Hagemann, Elaine R. Mardis, Obi Griffith, Malachi Griffith, Christopher A. Miller, Ted H. Hansen, Timothy P. Fleming, Robert D. Schreiber, William E. Gillanders
Publikováno v:
Genome Medicine, Vol 16, Iss 1, Pp 1-17 (2024)
Abstract Background Neoantigen vaccines can induce or enhance highly specific antitumor immune responses with minimal risk of autoimmunity. We have developed a neoantigen DNA vaccine platform capable of efficiently presenting both HLA class I and II
Externí odkaz:
https://doaj.org/article/361f87535f3347da8e2cfda87d75ab59
Autor:
Foluso O. Ademuyiwa, Donald W. Northfelt, Tracey O’Connor, Ellis Levine, Jingqin Luo, Yu Tao, Jeremy Hoog, Marie L. Laury, Tracy Summa, Trish Hammerschmidt, Zhanfang Guo, Ashley Frith, Katherine Weilbaecher, Mateusz Opyrchal, Rebecca Aft, Katherine Clifton, Rama Suresh, Nusayba Bagegni, Ian S. Hagemann, Michael D. Iglesia, Cynthia X. Ma
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-9 (2023)
Abstract Patients with ER+/HER2+ breast cancer (BC) are less likely to achieve pathological complete response (pCR) after chemotherapy with dual HER2 blockade than ER−/HER2+ BC. Endocrine therapy plus trastuzumab is effective in advanced ER+/HER2+
Externí odkaz:
https://doaj.org/article/49d5c74d8dba4b95b0b0ea0d7e2de4d4
Autor:
Jairam Krishnamurthy, Jingqin Luo, Rama Suresh, Foluso Ademuyiwa, Caron Rigden, Timothy Rearden, Katherine Clifton, Katherine Weilbaecher, Ashley Frith, Anna Roshal, Pavan K. Tandra, Mathew Cherian, Tracy Summa, Brittney Haas, Shana Thomas, Leonel Hernandez-Aya, Mattias Bergqvist, Lindsey Peterson, Cynthia X. Ma
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-7 (2022)
Abstract Palbociclib 3-weeks-on/1-week-off, combined with hormonal therapy, is approved for hormone receptor positive (HR+)/HER2-negative (HER2−) advanced/metastatic breast cancer (MBC). Neutropenia is the most frequent adverse event (AE). We aim t
Externí odkaz:
https://doaj.org/article/66f1f8841c624feda0766f004e302bc2
Autor:
Gregory Vlacich, Andrew Ballard, Shahed N. Badiyan, Matthew Spraker, Lauren Henke, Hyun Kim, A. Craig Lockhart, Haeseong Park, Rama Suresh, Yi Huang, Cliff G. Robinson, Jeffrey D. Bradley, Pamela P. Samson
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 30, Iss , Pp 19-25 (2021)
Background and purpose: Radiation dose escalation to improve poor outcomes with chemoradiation in locally advanced esophageal carcinoma is limited in part by increased toxicity. This Phase I study investigates the use of IMRT to improve tolerability
Externí odkaz:
https://doaj.org/article/579195d4e48d41639f46f0992f183039
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Stefania Merighi, Pier Andrea Borea, Katia Varani, Fabrizio Vincenzi, Alessia Travagli, Manuela Nigro, Silvia Pasquini, R. Rama Suresh, Sung Won Kim, Nora D. Volkow, Kenneth A. Jacobson, Stefania Gessi
Publikováno v:
Molecules, Vol 27, Iss 9, p 2680 (2022)
The A2A adenosine receptor is a protein belonging to a family of four GPCR adenosine receptors. It is involved in the regulation of several pathophysiological conditions in both the central nervous system and periphery. In the brain, its localization
Externí odkaz:
https://doaj.org/article/4913aae69c9f40a5aaaacc4f9eabe103
Autor:
Katherine K. Clifton, Shana N. Thomas, Jingqin Luo, Jing Xi, Nusayba A. Bagegni, Foluso O. Ademuyiwa, Rama Suresh, Ashley Frith, Andrew A. Davis, Ron Bose, Katherine Weilbaecher, Whitney L. Hensing, Timothy Pluard, Massimo Cristofanilli, Hyo S. Han, Adam M. Brufsky, Kevin Kalinsky, Shom Goel, Seth A. Wander, Lindsay L. Peterson, Cynthia Ma
Publikováno v:
Cancer Research. 83:PD13-09
Background: CDK4/6 inhibitors (CDK4/6i) paired with endocrine therapy (ET) are considered first-line (1L) therapy for patients (pts) with HR+ HER2- advanced breast cancer (aBC). A minority of pts will demonstrate primary resistance to CDK4/6i, as cha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc74005a8ddece22f16b5410d530c3b0
https://doi.org/10.1158/1538-7445.sabcs22-pd13-09
https://doi.org/10.1158/1538-7445.sabcs22-pd13-09
Autor:
Mara Hofherr, Jennifer Hedgecorth, Foluso O. Ademuyiwa, Lindsay L. Peterson, Nusayba A. Bagegni, Rama Suresh, Ashley Frith, Ron Bose, Katherine Weilbaecher, Cynthia Ma, Andrew A. Davis, Katherine K. Clifton
Publikováno v:
Cancer Research. 83:P3-06
Background: KEYNOTE-522 was a randomized, double-blind, placebo-controlled phase 3 trial which resulted in the FDA approval of pembrolizumab with neoadjuvant chemotherapy for patients (pts) with newly diagnosed, high-risk, early-stage triple negative
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::03f3aee1684b824be546a3580854b791
https://doi.org/10.1158/1538-7445.sabcs22-p3-06-06
https://doi.org/10.1158/1538-7445.sabcs22-p3-06-06
Autor:
Nusayba A. Bagegni, Isabella Grigsby, Leslie Nehring, Jingqin Luo, Jennifer Powers Carson, David W. Gibson, Meghan Horvath, Katherine K. Clifton, Foluso O. Ademuyiwa, Rama Suresh, Ashley Frith, Andrew A. Davis, Lindsay L. Peterson, Ron Bose, Amy Williams, Mattias Bergqvist, Cynthia Ma
Publikováno v:
Cancer Research. 83:OT3-11
Background: CDK 4/6i have altered the therapeutic landscape of HR+, HER2- MBC, improving progression free and overall survival (PFS and OS) compared to endocrine therapy (ET) alone. Despite durable responses to CDK 4/6i in a large majority of patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::63a87133567d701ddd8ff3a693c4164d
https://doi.org/10.1158/1538-7445.sabcs22-ot3-11-01
https://doi.org/10.1158/1538-7445.sabcs22-ot3-11-01
Autor:
Andrew A. Davis, Jingqin Luo, Tiantian Zheng, Chao Dai, Xiaoxi Dong, Lu Tan, Rama Suresh, Foluso O. Ademuyiwa, Caron Rigden, Timothy P. Rearden, Katherine Clifton, Katherine Weilbaecher, Ashley Frith, Pavan K. Tandra, Tracy Summa, Brittney Haas, Shana Thomas, Leonel F. Hernandez-Aya, Lindsay L. Peterson, Xiaohong Wang, Shujun J. Luo, Kemin Zhou, Pan Du, Shidong Jia, Bonnie L. King, Jairam Krishnamurthy, Cynthia X. Ma
Publikováno v:
Clinical Cancer Research. 29:1719-1729
Purpose: Clinical biomarkers to identify patients unlikely to benefit from CDK4/6 inhibition (CDK4/6i) in combination with endocrine therapy (ET) are lacking. We implemented a comprehensive circulating tumor DNA (ctDNA) analysis to identify genomic f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ec49acfada526637a14aa499abc0bffc
https://doi.org/10.1158/1078-0432.ccr-22-2177
https://doi.org/10.1158/1078-0432.ccr-22-2177